PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 02:15:16 2024-03-28 pm EDT 5-day change 1st Jan Change
29.36 USD -0.27% Intraday chart for PTC Therapeutics, Inc. -2.75% +6.46%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
PTC Therapeutics Seeks EMA Marketing Authorization for Sepiapterin for Phenylketonuria Treatment MT
PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA CI
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza? as a Treatment for AADC Deficiency CI
Transcript : PTC Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 04:05 PM
Transcript : PTC Therapeutics, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 01:30 PM
PTC Therapeutics Shares Jump Following Q4 Results MT
TD Cowen Cuts Price Target on PTC Therapeutics to $30 From $32, Maintains Market Perform Rating MT
RBC Raises Price Target on PTC Therapeutics to $28 From $22, Keeps Sector Perform Rating MT
PTC Therapeutics Q4 Loss Narrows, Sales Up; Sets Guidance; Shares Slump After-Hours MT
PTC Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : PTC Therapeutics, Inc., Q4 2023 Earnings Call, Feb 29, 2024
PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024 CI
Earnings Flash (PTCT) PTC THERAPEUTICS Posts Q4 Revenue $307.1M, vs. Street Est of $317.9M MT
PTC Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Sector Update: Health Care Stocks Higher Friday Afternoon MT
Cantor Fitzgerald Cuts PTC Therapeutics' Price Target to $45 From $51, Keeps Overweight Rating MT
Global markets live: LVMH, Intel, Tesla, Salesforce, Eli Lilly... Our Logo
Inflation is just the icing on the cake Our Logo
Sector Update: Health Care Stocks Mixed Premarket Friday MT
Sector Update: Health Care MT
RBC Cuts Price Target on PTC Therapeutics to $22 From $27 Amid Negative Opinion on Translarna From European Medicines Agency Committee; Sector Perform Kept MT
North American Morning Briefing : Intel Drags Down Chip Sector DJ
Stocks to Watch : Intel, PTC Therapeutics, KLA DJ
PTC Therapeutics' Muscle Disorder Drug Gets Negative Opinion From European Medicines Agency MT
Europe to withdraw PTC Therapeutics' rare muscle disorder drug RE
Chart PTC Therapeutics, Inc.
More charts
PTC Therapeutics, Inc. is a science-driven, global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. Its portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology, metabolism and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It also offers Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, and Evrysdi, a treatment for spinal muscular atrophy (SMA). Its splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease (HD).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
29.44 USD
Average target price
29.08 USD
Spread / Average Target
-1.21%
Consensus
  1. Stock
  2. Equities
  3. Stock PTC Therapeutics, Inc. - Nasdaq
  4. News PTC Therapeutics, Inc.
  5. Raymond James Adjusts PTC Therapeutics' Price Target to $60 From $55, Keeps Outperform Rating